Geriatric nursing (New York, N.Y.) · 2025
Examining pharmacological and demographic factors among male and female alzheimer's disease patients diagnosed with attention concentration disorder and cognitive communication disorder.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Desai Ashna, Agbomi Lidadi L, Nathaniel Adebobola I, Nathaniel Emmanuel I, Roley Laurie Theriot, Goodwin Richard, Nathaniel Thomas I
Аннотация
OBJECTIVE: This study examines the differences between male and female Alzheimer's Disease patients diagnosed with Attention Concentration Deficit (ADACD) and Cognitive Communicative Disorder (ADCCD), focusing on pharmacological and demographic factors.
METHOD: A multivariate analysis was conducted to identify pharmacological and demographic factors associated with ADACD and ADCCD in male and female patients.
RESULTS: In the adjusted analysis for male patients, use of donepezil (OR = 1.683, 95 % CI: 1.172-2.417, p = 0.005), and risperidone (Risperdal) use (OR = 3.177, 95 % CI: 1.841-5.484, p < 0.001) were significantly associated with ADCCD. The use of memantine (OR = 0.189, 95 % CI: 0.091-0.393, p < 0.001), aripiprazole (OR = 0.065, 95 % CI: 0.015-0.278, p < 0.001), were associated with ADACD. For female patients, citalopram use (OR = 2.470, 95 % CI: 1.751-3.484, p < 0.001) was associated with ADCCD.
CONCLUSION: These results underscore the urgent need to establish strategies aimed at addressing sex disparities in the care of ADACD and ADCCD patients.
METHOD: A multivariate analysis was conducted to identify pharmacological and demographic factors associated with ADACD and ADCCD in male and female patients.
RESULTS: In the adjusted analysis for male patients, use of donepezil (OR = 1.683, 95 % CI: 1.172-2.417, p = 0.005), and risperidone (Risperdal) use (OR = 3.177, 95 % CI: 1.841-5.484, p < 0.001) were significantly associated with ADCCD. The use of memantine (OR = 0.189, 95 % CI: 0.091-0.393, p < 0.001), aripiprazole (OR = 0.065, 95 % CI: 0.015-0.278, p < 0.001), were associated with ADACD. For female patients, citalopram use (OR = 2.470, 95 % CI: 1.751-3.484, p < 0.001) was associated with ADCCD.
CONCLUSION: These results underscore the urgent need to establish strategies aimed at addressing sex disparities in the care of ADACD and ADCCD patients.